+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of eloralintide in adults who are obese or overweight but do not have type 2 diabetes. This Phase 3 clinical trial aims to understand how eloralintide affects body weight and other health measures over time in this population. Participants will be randomly assigned to receive one of four different doses of eloralintide or a placebo, all given by subcutaneous injection. The main phase of the study lasts about 75 weeks, and participants with prediabetes may continue into an extension phase for an additional 2 years to further assess long-term effects. During the study, participants will have regular visits for assessments including body weight, body fat, waist circumference, blood pressure, blood tests, and questionnaires on overall health. Researchers will monitor changes from baseline up to week 64 and longer for some measures, including the time to develop type 2 diabetes. Safety and medication use will also be tracked throughout the study period.

Age: 18Years +All GendersPhase 3
158 locations
C

Actively Recruiting

Researchers are conducting a multicenter, prospective, randomized controlled trial to compare three types of haemostatic materialsHemocoll fibrillar Type-I collagen haemostat FTC, Avitene Microfibrillar Collagen Hemostat MCH, and conventional bone wax. The trial focuses on controlling bleeding from exposed cancellous bone in adults undergoing planned single-ray amputation involving phalangeal, metacarpal, or metatarsal bones. The main goal is to evaluate which material best achieves complete haemostasis at specific times after application, with Hemocoll FTC and Avitene MCH being directly compared primarily. Participants are randomly assigned to receive one of the three haemostatic materials applied directly to the exposed cancellous bone surface after the amputation, tourniquet release, and standardized soft-tissue haemostasis. A common compression method using sterile gauze and elastic crepe bandage is applied for 60 seconds across all groups. The primary haemostasis assessment times vary by anatomical site 2 minutes for phalanx, 3 minutes for metacarpal, and 5 minutes for metatarsal bones. Secondary comparisons include evaluating Hemocoll FTC versus bone wax and Avitene MCH versus bone wax. During the trial, participants will be monitored for haemostasis success, bleeding grades, time to haemostasis, and possible complications such as rebleeding or wound issues. Surgeons will also assess ease of application and material use. The study includes intraoperative assessments and follows participants for postoperative bleeding, hematoma, and adverse events related to the materials. The study plans to enroll 135 adults and expects to complete by January 2027.

Age: 18Years +All GendersPhase Not Applicable
3 locations
R

Actively Recruiting

This research investigates the treatment of diabetic foot ulcers DFUs by comparing two skin substitutes a high-purity type-I collagen-based skin substitute HPTC and an acellular intact fish skin matrix AFSM. The study enrolls patients with Wagner Grade 1-2 diabetic foot ulcers to evaluate which treatment, combined with standard wound care, leads to better healing outcomes. This randomized controlled clinical trial is conducted at multiple centers in India and Bangladesh to assess safety and effectiveness. Participants are randomly assigned to receive either HPTC or AFSM, each applied weekly or as needed, followed by a padded 3-layer dressing that includes non-adherent paraffin gauze, absorbent gauze pads, and a soft crepe bandage. Some participants may join an optional sub-study involving small biopsies from the wound edge for detailed tissue analysis. The primary outcome is the proportion of participants achieving complete wound closure by Week 12, with assessments confirmed about a week later. During the trial, participants attend scheduled visits where wound healing is closely monitored through digital imaging and expert evaluation. Additional measurements include wound area reduction over time, scar quality, quality of life, and ulcer recurrence up to Week 13. Safety is tracked by recording any adverse events, and participants must follow prescribed off-loading methods and attend all study visits. The total participation duration is approximately 13 weeks from treatment start to final assessment.

Age: 18Years - 75YearsAll GendersPhase Not Applicable
4 locations